AVITA Medical Inc. is a commercial stage regenerative tissue company in the United States, Australia, and the United Kingdom. The company is headquartered in Valencia, California.
| Revenue (TTM) | $72.35M |
| Gross Profit (TTM) | $58.86M |
| EBITDA | $-37.11M |
| Operating Margin | -45.70% |
| Return on Equity | -1746.00% |
| Return on Assets | -40.80% |
| Revenue/Share (TTM) | $2.50 |
| Book Value | $-0.75 |
| Price-to-Book | 40.95 |
| Price-to-Sales (TTM) | 2.13 |
| EV/Revenue | 2.676 |
| EV/EBITDA | -6.17 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 4.00% |
| Shares Outstanding | $30.78M |
| Float | $30.30M |
| % Insiders | 1.52% |
| % Institutions | 17.15% |
Volatility is currently expanding
Avita Medical (RCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Prepared Remarks Transcript
AVITA Medical, Inc. (RCEL) Discusses Business Progress, Operational Changes and Sequential Revenue Growth Transcript
VALENCIA, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, President and Chief Executive Officer, and David O'Toole, Chief Financial Officer, on May 20, 2026, at 4:00 p.m.
Avita Medical NASDAQ: RCEL reported first-quarter 2026 revenue growth and reaffirmed its full-year outlook as management said reimbursement conditions for its RECELL product are normalizing and demand patterns are becoming more consistent.
VALENCIA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the first quarter ended March 31, 2026.
Board appoints Cary Vance as President and Chief Executive Officer Follows successful interim tenure and thorough search process by the Board Jan Stern Reed elected as Chair of the AVITA Medical Board VALENCIA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that its Board of Directors has appointed Cary Vance as President and Chief Executive Officer, effective immediately.
RECELL GO® receives regulatory clearance in Australia and New Zealand, enabling commercialization across both markets RECELL GO is AVITA Medical's next-generation system that automates and standardizes the preparation of RECELL ® Spray-On Skin™ for the treatment of burn and trauma wounds VALENCIA, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that RECELL GO, its next-generation system for preparing RECELL Spray-On Skin, has received certification from Australia's Therapeutic Goods Administration (“TGA”) and has been listed on New Zealand's Web Assisted Notification of Devices (“WAND”) database by Medsafe, enabling commercialization in both markets for burn and acute wound treatment.
VALENCIA, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that it will report its first quarter 2026 financial results after the close of the U.S. financial markets on Thursday, May 14, 2026.
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AVITA Medical Inc. (“AVITA Medical” or the “Company”) (NASDAQ: RCEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
